The predictability of TMB quantified by targeted next-generation sequencing (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets) combined with PD-L1 expression was further validated in tumor tissues (1-year PFS: AUC, 0.826; 3-year PFS: AUC, 0.948) (Figure 3C and D). This evidence concerns the gene CD274 and neoplasm.